LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

Search

Ionis Pharmaceuticals Inc

Abierto

SectorSalud

82.35 2.8

Resumen

Variación precio

24h

Actual

Mínimo

79.9

Máximo

82.56

Métricas clave

By Trading Economics

Ingresos

-252M

-129M

Ventas

-295M

157M

BPA

-0.613

Margen de beneficio

-82.062

Empleados

1,069

EBITDA

-245M

-94M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+8.25% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.1B

13B

Apertura anterior

79.55

Cierre anterior

82.35

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

361 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

25 nov 2025, 16:56 UTC

Ganancias
Principales Movimientos del Mercado

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25 nov 2025, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 nov 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25 nov 2025, 22:39 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

25 nov 2025, 22:39 UTC

Charlas de Mercado

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25 nov 2025, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

25 nov 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

25 nov 2025, 21:38 UTC

Ganancias

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25 nov 2025, 21:31 UTC

Charlas de Mercado

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25 nov 2025, 21:27 UTC

Ganancias

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25 nov 2025, 21:20 UTC

Ganancias

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25 nov 2025, 21:18 UTC

Ganancias

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25 nov 2025, 21:15 UTC

Ganancias

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25 nov 2025, 20:16 UTC

Charlas de Mercado

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25 nov 2025, 18:42 UTC

Charlas de Mercado

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25 nov 2025, 18:25 UTC

Adquisiciones, fusiones, absorciones

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25 nov 2025, 17:30 UTC

Charlas de Mercado

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25 nov 2025, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

25 nov 2025, 17:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

25 nov 2025, 16:33 UTC

Adquisiciones, fusiones, absorciones

Eni: Financial Details Weren't Disclosed

25 nov 2025, 16:33 UTC

Adquisiciones, fusiones, absorciones

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25 nov 2025, 16:32 UTC

Adquisiciones, fusiones, absorciones

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25 nov 2025, 16:31 UTC

Adquisiciones, fusiones, absorciones

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25 nov 2025, 16:30 UTC

Adquisiciones, fusiones, absorciones

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25 nov 2025, 16:23 UTC

Ganancias

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25 nov 2025, 16:12 UTC

Charlas de Mercado

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25 nov 2025, 16:11 UTC

Charlas de Mercado

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25 nov 2025, 16:10 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 nov 2025, 16:10 UTC

Charlas de Mercado

Sterling Could Briefly Rise After Budget -- Market Talk

25 nov 2025, 16:10 UTC

Charlas de Mercado

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

8.25% repunte

Estimación a 12 meses

Media 85 USD  8.25%

Máximo 110 USD

Mínimo 65 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

19 ratings

16

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

361 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat